Last updated: September 24, 2026
Benazepril hydrochloride is an off-patent, immediate-release ACE inhibitor marketed primarily as generic oral tablets. The strongest commercial opportunities are low-cost tablet manufacturing, differentiated dosage forms, fixed-dose combinations, pediatric liquid systems, and supply-chain improvements. Patent exclusivity is no longer the main barrier. Formulation performance, regulatory execution, bioequivalence, manufacturing cost, and channel access determine commercial value.
What is the regulatory and commercial status of benazepril hydrochloride?
Benazepril hydrochloride is the hydrochloride salt of benazepril, an orally administered prodrug converted to the active metabolite benazeprilat. The reference product, Lotensin, was approved by the FDA for hypertension and is associated with Novartis, following the earlier Roche commercialization history. FDA-approved strengths include 5 mg, 10 mg, 20 mg, and 40 mg tablets.[1]
| Attribute |
Benazepril hydrochloride |
| Therapeutic class |
Angiotensin-converting enzyme inhibitor |
| Active moiety |
Benazepril |
| Active metabolite |
Benazeprilat |
| Dosage form |
Immediate-release oral tablet |
| Approved strengths |
5 mg, 10 mg, 20 mg, 40 mg |
| Primary indication |
Hypertension |
| FDA pathway |
Abbreviated New Drug Application for generics |
| Reference product |
Lotensin |
| Biosimilar pathway |
Not applicable |
| Current competitive basis |
Price, supply reliability, dosage-form convenience, combination products |
| Primary formulation challenge |
Reproducible dissolution and tablet robustness at low dose |
The product is a small-molecule generic, not a biologic. Biosimilar competition is therefore irrelevant. Generic applicants compete through ANDAs, typically using a bioequivalence study and comparative dissolution data rather than clinical efficacy trials.
When did benazepril hydrochloride lose exclusivity?
Benazepril hydrochloride has lost its original regulatory and patent exclusivity. The current commercial market is generic.
The Orange Book is the principal FDA source for listed patents, exclusivity periods, therapeutic equivalence codes, and reference-product information.[2] For benazepril hydrochloride, the commercial significance of the Orange Book is now primarily substitution and reference-product status rather than an active patent barrier.
Patent and exclusivity timeline
| Milestone |
Commercial significance |
| Original Lotensin approval |
Established the reference product and clinical labeling |
| Expiration of original product and formulation protections |
Opened the market to ANDA applicants |
| Generic approvals |
Created multi-source pricing and pharmacy substitution |
| Current market |
Primarily governed by manufacturing economics and distribution access |
No commercially meaningful unexpired composition-of-matter exclusivity remains for benazepril hydrochloride tablets. Any applicant evaluating the product should distinguish between expired historical patents and currently enforceable rights.
What patents protect benazepril hydrochloride products?
The principal historical protection covered the benazepril molecule and its pharmaceutical use. Those rights have expired. Current product differentiation is more likely to arise from formulation, process, device, combination, or manufacturing patents than from the active ingredient itself.
Patent categories relevant to a new product
| Patent category |
Relevance to benazepril hydrochloride |
| Composition of matter |
Expired for the established active ingredient |
| Salt or polymorph |
Potentially relevant only if a genuinely distinct, patentable solid form is developed |
| Immediate-release tablet |
Usually weak unless tied to a specific composition or performance result |
| Taste masking |
Relevant for orally disintegrating or liquid products |
| Modified release |
Potentially valuable but requires clinical and pharmacokinetic development |
| Fixed-dose combination |
Potential source of new patent claims and regulatory differentiation |
| Manufacturing process |
Relevant where it reduces impurities, improves yield, or controls particle properties |
| Packaging and moisture protection |
Usually supports product quality rather than market exclusivity alone |
| Method of use |
Limited value for established hypertension treatment unless tied to a new, specific indication |
A formulation patent must provide more than a routine excipient substitution. Stronger claims would typically require a defined composition, a reproducible manufacturing process, and an unexpected technical result such as improved stability, dissolution, content uniformity, or patient acceptability.
What excipients are used in benazepril hydrochloride tablets?
Approved products use conventional tablet excipients. Exact composition varies by manufacturer and strength. Label sources identify inactive ingredients such as lactose, microcrystalline cellulose, crospovidone, colloidal silicon dioxide, magnesium stearate, hypromellose, titanium dioxide, and colorants in various products.[1,3]
The excipient strategy should account for the low drug load in the 5 mg strength and the need for consistent dissolution across all strengths.
Functional excipient roles
| Excipient function |
Candidate materials |
Commercial purpose |
| Diluent |
Lactose, microcrystalline cellulose, dibasic calcium phosphate |
Provides tablet mass and improves content uniformity |
| Binder |
Povidone, copovidone, pregelatinized starch |
Improves granule and tablet strength |
| Disintegrant |
Crospovidone, croscarmellose sodium, sodium starch glycolate |
Supports rapid tablet breakup |
| Glidant |
Colloidal silicon dioxide |
Improves powder flow |
| Lubricant |
Magnesium stearate, sodium stearyl fumarate |
Reduces sticking and ejection force |
| Film former |
Hypromellose |
Protects the core and improves appearance |
| Opacifier |
Titanium dioxide |
Supports light protection and appearance |
| Colorant |
Approved iron oxides or other permitted colorants |
Strength identification and branding |
| Liquid suspending agent |
Hypromellose, xanthan gum, microcrystalline cellulose blends |
Supports pediatric or extemporaneous liquid systems |
| Sweetener and flavor |
Sucralose, sorbitol, fruit flavors |
Improves acceptance of liquid or orally disintegrating dosage forms |
Excipient selection should be validated against assay, content uniformity, hardness, friability, disintegration, dissolution, impurity profile, and stability.
How should the excipient strategy address benazepril hydrochloride formulation risks?
The formulation program should prioritize robust powder handling, fast and reproducible dissolution, and protection against moisture-related variability.
Low-dose content uniformity
The 5 mg tablet presents the greatest content-uniformity challenge because the active represents a relatively small portion of total tablet mass. Direct compression can be commercially attractive but requires controlled particle size, segregation testing, and validated blending. Wet granulation may improve uniformity and flow but adds water, heat, and processing complexity.
A practical development sequence is:
- Screen direct compression with microcrystalline cellulose and a co-processed excipient.
- Evaluate dry granulation if flow or segregation is unacceptable.
- Use wet granulation only where it materially improves uniformity or tablet robustness.
- Confirm that lubrication does not slow dissolution.
Dissolution control
A high-disintegrant formulation can provide rapid tablet breakup, but excessive disintegrant or over-lubrication can produce variable dissolution. Crospovidone and croscarmellose sodium are logical first-line candidates. Sodium starch glycolate may provide stronger swelling but can be more sensitive to formulation and compression conditions.
The target should be a dissolution profile that remains consistent across manufacturing lots, tablet strengths, and realistic storage conditions.
Moisture and hydrolytic stability
Benazepril contains ester functionality and is converted in vivo to benazeprilat. The formulation should therefore be evaluated for hydrolytic degradation, particularly under elevated humidity. Moisture control can involve:
- Low-moisture excipient grades.
- Controlled granulation conditions.
- High-barrier blister packaging.
- Desiccant-containing bottles.
- Film coating where it improves protection.
- Water-activity monitoring during development and scale-up.
Packaging may produce more commercial value than a complex excipient system if the primary failure mode is moisture exposure during distribution.
Lubrication and compression
Magnesium stearate concentration and mixing time should be tightly controlled. Excessive lubrication can reduce tablet tensile strength and delay wetting. Sodium stearyl fumarate may be evaluated where a less hydrophobic lubricant profile improves dissolution, although cost and supply considerations may favor magnesium stearate.
What formulation patents could create commercial differentiation?
The most credible formulation opportunities are products that solve a defined administration or adherence problem.
Orally disintegrating tablets
An orally disintegrating benazepril product could target patients with dysphagia, elderly patients, or those who have difficulty swallowing conventional tablets. The formulation would require:
- Rapid in-mouth disintegration.
- Acceptable taste.
- Low friability.
- Adequate moisture protection.
- Demonstrated dose uniformity.
- A regulatory bridge to the approved immediate-release tablet.
Taste masking is material because benazepril hydrochloride may produce an unpleasant oral sensation. Ion-exchange resins, polymer coatings, cyclodextrins, flavor systems, and rapidly dispersible granules are potential approaches. The commercial opportunity is larger if the product provides a meaningful administration benefit rather than only a different tablet appearance.
Pediatric oral liquid
A ready-to-use suspension or powder-for-reconstitution could address patients unable to swallow tablets. The development program would need to establish:
- Chemical and physical stability through the labeled in-use period.
- Uniform dose delivery after shaking.
- Syringe or cup dosing accuracy.
- Preservative effectiveness where applicable.
- Palatability.
- Compatibility with the container-closure system.
A liquid may receive limited demand because hypertension treatment is concentrated in adults, but it can support hospital, pediatric, specialty-pharmacy, and compounding-related channels.
Modified-release products
Modified release is technically possible but commercially difficult. Benazepril is generally dosed once or twice daily depending on patient factors and labeling. A modified-release product would require pharmacokinetic development, food-effect evaluation, and a clear clinical or adherence advantage. It would not be a simple ANDA-style extension if the dosage form materially changes exposure.
Fixed-dose combinations
Fixed-dose combinations are the most commercially relevant expansion area. Benazepril can be paired with hydrochlorothiazide, amlodipine, or other antihypertensive agents. Combination products can improve adherence and reduce pill burden, but they face:
- Dose-ratio selection.
- Interaction and stability assessment.
- Separate dissolution requirements.
- Clinical bridging or combination-product requirements.
- Competition from established ACE inhibitor combinations.
A differentiated benazepril combination would need either a favorable price, a useful dose range, a supply advantage, or a formulation benefit.
What FDA regulatory pathway applies to new benazepril products?
A conventional immediate-release generic tablet typically proceeds through an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug.[4]
Regulatory pathways by product type
| Product concept |
Likely pathway |
| Conventional immediate-release tablet |
ANDA |
| Different strength within an established product line |
ANDA strength supplement or new ANDA strategy, depending on facts |
| Oral suspension with no equivalent reference dosage form |
505(b)(2) may be relevant |
| Orally disintegrating tablet |
ANDA or 505(b)(2), depending on formulation and reference-product relationship |
| Modified-release product |
Often 505(b)(2) or a more extensive development route |
| Fixed-dose combination |
505(b)(2), ANDA, or full application depending on listed reference products and formulation |
FDA guidance on ANDAs, bioequivalence, dissolution, inactive ingredients, and labeling governs the development package.[4,5]
Are Paragraph IV challenges relevant to benazepril hydrochloride?
Paragraph IV litigation is no longer the central market issue for conventional benazepril hydrochloride tablets because the original patent estate has expired. A Paragraph IV certification would become relevant only if an applicant confronts a currently listed patent for a particular reference product or reformulated product.
For a new formulation, the risk assessment should cover:
- Orange Book-listed patents.
- Non-Orange-Book formulation patents.
- Process patents.
- Use patents.
- Patent term adjustment and patent term extension.
- Licensing restrictions.
- Prior settlements involving the specific formulation.
A Paragraph IV strategy has greater commercial value for a newly protected fixed-dose combination, modified-release product, or branded specialty formulation than for a standard benazepril tablet.
What is the Orange Book status of benazepril hydrochloride?
The Orange Book identifies approved reference products and therapeutically equivalent generic products. For a standard benazepril hydrochloride tablet, the relevant commercial questions are:
- Whether the reference product remains listed.
- Which generic products have an “A” therapeutic-equivalence rating.
- Whether any unexpired patents or exclusivity codes remain.
- Whether the listed reference product is available for ANDA comparison.
- Whether the applicant can obtain reliable reference batches.
The absence of a current patent barrier does not guarantee commercial success. The market can remain difficult because multiple suppliers compete on narrow margins and pharmacy purchasers favor reliable, low-cost sources.
Which companies are challenging or competing with benazepril hydrochloride?
Competition comes mainly from generic manufacturers and distributors rather than branded patent challengers. Publicly marketed generic ACE inhibitor competitors include products containing lisinopril, enalapril, ramipril, quinapril, and perindopril, subject to country-specific availability.
| Competitive segment |
Main pressure on benazepril |
| Generic benazepril tablets |
Direct price competition |
| Lisinopril |
Broad prescribing and low-cost supply |
| Enalapril |
Established ACE inhibitor alternative |
| Ramipril |
Cardiovascular and risk-reduction positioning |
| ARBs |
Alternative for ACE-inhibitor intolerance |
| Fixed-dose combinations |
Reduced pill burden |
| Hospital suppliers |
Contract pricing and supply reliability |
Benazepril can remain commercially viable where suppliers offer dependable inventory, broad strength coverage, competitive contract pricing, and a differentiated dosage form.
What generic launch risks exist?
Generic launch risk is moderate for a conventional tablet and higher for differentiated formulations.
Conventional tablet risks
- Low selling prices caused by multi-source competition.
- Limited gross margin at the 5 mg strength.
- Price erosion after additional ANDA approvals.
- API and excipient supply interruptions.
- Reference-product sourcing problems.
- Dissolution or stability failures during scale-up.
- Contract-manufacturing capacity constraints.
Differentiated formulation risks
- Insufficient patient demand.
- Bioequivalence failure caused by altered release or absorption.
- Taste-masking failure.
- Higher packaging cost.
- Limited reimbursement for premium generic presentations.
- Patent claims that cover the formulation or combination.
- Increased pharmacovigilance and lifecycle-management requirements.
How strong is the patent estate for benazepril hydrochloride?
The conventional benazepril hydrochloride patent estate is weak because the core product is mature and generic. Patent strength is higher only where a company owns a technically specific, commercially useful formulation or combination.
| Asset type |
Estimated strategic strength |
| Core benazepril molecule |
Low; expired |
| Standard immediate-release tablet |
Low |
| Moisture-protective packaging |
Low to moderate |
| Orally disintegrating formulation |
Moderate if supported by strong claims and data |
| Pediatric liquid |
Moderate if stability and dosing claims are defensible |
| Fixed-dose combination |
Moderate, depending on composition and indication |
| Novel modified release |
Moderate to high, but development risk is high |
| Manufacturing process |
Moderate where it materially improves yield or impurity control |
The strongest practical moat may be regulatory execution, supply reliability, formulation know-how, and customer contracts rather than enforceable patent exclusivity.
What licensing deals and commercial partnerships are available?
The largest realistic partnership opportunities involve:
- Contract development and manufacturing.
- Regional generic commercialization.
- Hospital and government supply contracts.
- Fixed-dose combination development.
- Pediatric formulation licensing.
- Specialty-pharmacy distribution.
- API sourcing and dual-supplier arrangements.
A licensing deal for conventional benazepril tablets would generally have limited value unless it includes a protected formulation, an established sales channel, regulatory approvals in multiple jurisdictions, or guaranteed manufacturing capacity.
Historical commercialization involved the reference product and its predecessor companies, while current opportunity is primarily generic and regional. Publicly available information does not establish a current, material branded licensing arrangement that controls the ordinary benazepril hydrochloride tablet market.
What revenue exposure and commercial opportunities exist?
Revenue potential is strongest in products that increase margin per prescription or secure institutional volume.
Opportunity ranking
| Opportunity |
Market attractiveness |
Development complexity |
Patent potential |
| Low-cost 5 mg to 40 mg tablet portfolio |
Moderate |
Low |
Low |
| High-barrier packaging and reliable supply |
Moderate |
Low to moderate |
Low |
| Orally disintegrating tablet |
Moderate |
Moderate |
Moderate |
| Pediatric liquid |
Niche |
Moderate |
Moderate |
| Benazepril/hydrochlorothiazide combination |
Moderate |
Moderate |
Moderate |
| Benazepril/amlodipine combination |
Moderate |
Moderate to high |
Moderate |
| Modified-release product |
Uncertain |
High |
High |
| Hospital and government contracts |
Moderate |
Low |
None |
The standard tablet market is likely to be volume-driven. Differentiated products can command better economics, but only where the formulation addresses an identifiable clinical or procurement problem.
What geographic markets are most attractive?
Benazepril availability and prescribing differ by country. The U.S. market offers an established ANDA framework but intense generic competition. European and Asian markets may provide opportunities through national registrations, local manufacturing, hospital tenders, or combination products.
Geographic strategy should consider:
- Local reference-product status.
- Patent and data-exclusivity rules.
- National essential-medicine lists.
- Tender concentration.
- API import requirements.
- Local-language labeling.
- Stability-zone requirements.
- Pharmacy substitution rules.
- Reimbursement and procurement pricing.
A product developed for global use should use excipients and packaging compatible with multiple climatic zones, including high-temperature and high-humidity conditions.
Key Takeaways
- Benazepril hydrochloride is a mature, off-patent small-molecule ACE inhibitor.
- Conventional tablets are regulated primarily through the ANDA pathway.
- The core active ingredient offers little current patent protection.
- Excipient strategy should focus on low-dose content uniformity, rapid dissolution, compression robustness, and moisture control.
- Crospovidone, croscarmellose sodium, microcrystalline cellulose, lactose, colloidal silicon dioxide, and magnesium stearate are practical starting points for immediate-release tablets.
- Orally disintegrating tablets, pediatric liquids, and fixed-dose combinations offer the most credible formulation opportunities.
- Biosimilar risk is not applicable.
- Paragraph IV risk is limited for ordinary tablets but can re-emerge with new reference products or protected formulations.
- Commercial success depends on cost, supply reliability, channel access, and product differentiation.
- The most defensible commercial moat is likely a combination of formulation know-how, regulatory execution, manufacturing capability, and distribution contracts.
FAQs
Can benazepril hydrochloride be formulated as an orally disintegrating tablet?
Yes. An orally disintegrating tablet is technically feasible, but taste masking, moisture protection, friability, dissolution, and bioequivalence must be demonstrated.
Which excipient is most important for the 5 mg benazepril tablet?
The most important excipient system is usually the diluent and binder combination because the low active load creates content-uniformity and segregation risks. Microcrystalline cellulose, lactose, and a controlled granulation process are common development options.
Is benazepril hydrochloride suitable for a pediatric formulation?
Yes, a suspension or powder-for-reconstitution could be developed. The main requirements are chemical stability, dose uniformity, palatability, preservative control, and accurate oral-syringe delivery.
Can a benazepril fixed-dose combination obtain new patent protection?
Yes, but protection would depend on the specific composition, dose ratio, formulation, manufacturing process, or clinical use. A routine combination of known ingredients may face substantial patentability challenges.
Does benazepril hydrochloride require biosimilar development?
No. Benazepril hydrochloride is a conventional small-molecule drug. Generic development uses the ANDA framework or, for certain new formulations and combinations, a 505(b)(2) application.
References
- U.S. Food and Drug Administration. (2023). Lotensin (benazepril hydrochloride) prescribing information.
- U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- DailyMed. (2024). Benazepril hydrochloride tablet: labeling and inactive ingredients. National Library of Medicine.
- U.S. Food and Drug Administration. (2009). Abbreviated new drug application submissions: Refuse-to-receive standards.
- U.S. Food and Drug Administration. (2015). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system.
